Results 51 to 60 of about 1,686,994 (258)
Przegląd Dermatologiczny, 2020 Urticaria has a complex aetiology and pathogenesis, and is characterized by the presence of wheals with accompanying pruritus or skin burning sensation. In 40% of cases, urticaria may be accompanied by angioedema. Depending on the duration, urticaria may
doaj +1 more source
FEATURES OF IMMUNE RESPONSE AND BASOPHIL ACTIVATION IN CHILDREN WITH CHRONIC URTICARIA
Медицинская иммунология, 2015 Some features of peripheral bood basophil activation were studied in children with different types of chronic urticaria, in order to specify the sustaining mechanisms of chronic urticaria.
N. A. Sinelnikova +2 more
doaj +1 more source
Arthritis &Rheumatology, EarlyView.Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf +15 more
wiley +1 more source
Other Interventions for Chronic Urticaria
177206High quality evidence for interventions in chronic urticaria is mainly confined to second generation H1 antihistamines, introduced in the 1980s, and omalizumab, approved for chronic spontaneous urticaria in 2014.
Grattan, Ceh E.H. +2 more
core +1 more source
Navigating adverse immunostimulation: A practical guide for clinical researchers
British Journal of Clinical Pharmacology, EarlyView.Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort +3 more
wiley +1 more source
Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
Allergy, Asthma & Clinical Immunology, 2023 Background While both the AAAAI/ACAAI and the EAACI/GA2LEN/EuroGuiDerm/APAAACI guidelines recommend starting cyclosporine for patients with chronic urticaria who have had an inadequate response to omalizumab, many clinicians are hesitant to initiate ...
Anthony F. LaCava, Olajumoke O. Fadugba
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Journal of Dermatology and Dermatologic Surgery, 2015 Background: Chronic urticaria (CU) is a multifactorial disease, however, in a majority of patients, it is not possible to ascribe a specific aetiology, which is termed ‘idiopathic’. Although autoimmunity has been implicated as a principal cause in 30–50%
Samia Aleem, Qazi Masood, Iffat Hassan
doaj +1 more source
The principles of contemporary management of chronic urticaria [PDF]
, 2019 Laboratorul de gastroenterologie, IP USMF Nicolae TestemițanuChronic urticaria (CU) and angioedema are widespread cutaneous diseases that have a negative impact on the quality of life.
Gribiniuc, Anatolie +2 more
core
British Journal of Clinical Pharmacology, EarlyView.Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar +6 more
wiley +1 more source